Latest Breaking News On - Ted snyder - Page 1 : comparemela.com
let s bring in michael ye and another health care analyst. michael, first you to. given the deals that we have seen, not just today but in the past, why do you believe a biomarine or vertex may be takeout targets down the line? two reasons. one is if you looked at biotech valuations, they re down 35% off the top in the last 6 to 8 months on political rhetoric that we talked about. so asset prices have come down and become a lot more attractive. the second point is that there s no change to the fact that big companies need commercial products and they need pipeline. that s exactly what you re seeing. and what will those companies have that make them attractive you to or to potentially bottom? les, we can hear you. we ll get to you in a second. what makes them potential buyout candidates? both vertex and biomerine have real revenue. they re out there right now plus pipelines. you get both of those with that. and so both of these companies have asset value to acquirers
AustraliaShanghaiChinaBeijingCaliforniaUnited-statesSyriaRussiaSyracuseNew-yorkWashingtonDistrict-of-columbia